ARRAY BIOPHARMA INC's ticker is ARRY and the CUSIP is 04269X105. A total of 171 filers reported holding ARRAY BIOPHARMA INC in Q4 2016. The put-call ratio across all filers is 0.59 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $230,161,000 | -10.1% | 4,967,892 | -52.7% | 0.12% | -10.9% |
| Q1 2019 | $256,040,000 | +90.8% | 10,502,369 | +11.5% | 0.14% | +69.1% |
| Q4 2018 | $134,180,000 | +11.9% | 9,416,202 | +19.3% | 0.08% | +35.0% |
| Q3 2018 | $119,958,000 | -13.8% | 7,891,940 | -4.9% | 0.06% | -15.5% |
| Q2 2018 | $139,243,000 | +3.7% | 8,298,126 | +0.9% | 0.07% | +4.4% |
| Q1 2018 | $134,212,000 | +14.3% | 8,223,767 | -10.3% | 0.07% | +21.4% |
| Q4 2017 | $117,374,000 | +16.5% | 9,169,836 | +12.0% | 0.06% | +14.3% |
| Q3 2017 | $100,747,000 | +34.5% | 8,190,764 | -8.5% | 0.05% | +32.4% |
| Q2 2017 | $74,920,000 | +38.9% | 8,950,982 | +48.4% | 0.04% | +37.0% |
| Q1 2017 | $53,933,000 | +10.0% | 6,032,826 | +8.1% | 0.03% | +8.0% |
| Q4 2016 | $49,037,000 | +67.7% | 5,578,760 | +28.8% | 0.02% | +66.7% |
| Q3 2016 | $29,235,000 | – | 4,331,100 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Redmile Group, LLC | 16,618,776 | $146,079,000 | 12.59% |
| BVF INC/IL | 4,986,186 | $43,829,000 | 8.81% |
| First Light Asset Management, LLC | 1,000,361 | $8,793,000 | 3.86% |
| Crosspoint Capital Strategies, LLC | 463,005 | $4,070,000 | 3.62% |
| Consonance Capital Management LP | 2,723,471 | $23,912,000 | 2.63% |
| KOPP INVESTMENT ADVISORS LLC | 219,926 | $1,933,000 | 2.04% |
| SPHERA FUNDS MANAGEMENT LTD. | 900,000 | $7,911,000 | 2.00% |
| Orbimed Advisors | 16,088,800 | $141,421,000 | 1.80% |
| Cormorant Asset Management, LP | 1,150,000 | $10,109,000 | 1.36% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 2,073,680 | $18,227,000 | 1.26% |